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Non-structured abstract 
An increase in the fracture risk was reported in patients with type 2 diabetes mellitus 
(T2DM) treated with canagliflozin, possibly mediated by effects induced by all 
members of the sodium-glucose co-transporter 2 inhibitors (SGLT2i) class. It is 
unclear whether initiation of dapagliflozin is followed by an increase in the risk of 
fracture. Therefore, we performed a population-based, open cohort study was 
performed (January 2013-January 2016) using The Health Improvement Network 
(THIN). 22,618 patients with T2DM (4,548 exposed to dapagliflozin and 18,070 
under standard antidiabetic treatment, matched for age and sex) with no history of 
fractures at baseline. The primary outcome was the occurrence of any fragility 
fracture during the observation period. Risk of any fracture served as a secondary 
outcome. Adjusted Hazard Rate Ratios (aHR) with 95% confidence intervals (CI) 
were calculated using Cox regression. A total of 289 fractures (132 fragility fractures) 
were recorded during the observation period. No difference in the risk of fragility 
fracture was detected between patients prescribed dapagliflozin and matched controls 
(Crude HR: 0.90, 95% CI: 0.59-1.39, p-value = 0.645 and adjusted HR: 0.87, 95% CI: 
0.56-1.35, p-value = 0.531). Similarly, no difference in the risk of any fracture was 
detected (aHR: 0.89, 95% CI: 0.66-1.20, p-value =0.427). Sensitivity analyses limited 
to the subset of the population at high risk of fracture produced similar results. Thus, 
there was no evidence to suggest an increase in the risk of treatment-emergent 
fractures in patients with T2DM being initiated treatment with dapagliflozin.  
Word count: 244 
 
Keywords: THERAPEUTICS; sodium-glucose co-transporter inhibitors; STATISTICAL 
METHODS; PRACTICE/POLICY-RELATED ISSUES; Fracture risk assessment 
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Introduction  
Patients with type 2 diabetes mellitus (T2DM) are at an increased risk for osteoporotic 
fractures (1). Notably, fragility fractures in the context of T2DM-related osteoporosis 
are associated with increased mortality (2). Therefore, any factor that might (even 
incrementally) affect this risk should be of concern in the management of T2DM.  
 The less-pronounced systemic effects of sodium-glucose co-transporters 2 
(SGLT2i) inhibitors (canaglifozin, dapagliflozin and empaglifozin) are not yet fully 
elucidated. In specific, concerns are raised about their potential detrimental effect on 
the skeleton and eventually on the risk of fracture. In line with evidence suggesting a 
decrease in total hip body mass density (3) and increased risk of fractures in the upper 
and lower extremities (4), the rate of any fracture was recently found to be higher 
with canagliflozin in the CANVAS trial [hazard ratio (HR), 1.26]  (5). Dapagliflozin 
was also associated with increased risk of fractures in patients with moderate renal 
impairment in a small study involving 252 individuals (6). However, outcomes were 
too few, sample was distinct from the general diabetic population and considering the 
neutral effect of dapagliflozin on bone turnover markers (7,8), it is still unclear 
whether the fracture risk is higher in these patients. 
Therefore, we explored whether initiating treatment with dapagliflozin in 
patients with T2DM and no evidence of fractures at baseline is associated with an 
increased risk of fractures in the short term.  
 
Materials and Methods 
Study design: We designed and performed a population-based, retrospective open 
cohort study in which patients exposed to dapagliflozin (exposed cohort) were 
compared to matched patients with T2DM unexposed to SGLT2i (unexposed or 
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control cohort). Age, sex, body mass index (BMI) and duration of T2DM were used 
as matching parameters using a computerized procedure (9). Data were derived from 
The Health Improvement Network (THIN), a UK general practice electronic database, 
from 1st Jan 2013 (study start) to 1st Jan 2016 (study end, last collection date).  
Study cohort: Individuals were included in the exposed cohort if they (i) were aged 
40+ years, (ii) had more than three months of treatment with a dapagliflozin, (iii) 
remained at their practice at least three months after treatment initiation. For each 
exposed patient, up to four unexposed controls were selected by matching. Controls 
were also required to have a diagnosis of T2DM before or at their index date and were 
not exposed to any SGLT2i throughout the study.  
Follow- up, outcomes and covariates:  The primary outcome was an incident fragility 
fracture (vertebral, femoral, humerus, distal radius) identified during the observation 
period. Incidence of any fracture served as a secondary outcome. Estimated 
glomerular filtration rate, HbA1c, insulin therapy, anti-osteoporotic medications, 
metastatic bone disease, connective tissue disorder, hyperthyroidism, active smoking, 
social deprivation quintile and oral steroid treatment were used as covariates in the 
primary analysis. 
Sensitivity analyses: We performed pre-planned sensitivity analyses by (i) limiting to 
patients considered to be at a higher risk of fracture and (ii) adding use of 
thiazolidinediones (TZD) or sulfonylureas (SU) as covariates in the primary analysis. 
In the former, patients were considered to be at a higher risk of fracture if they were 
either at 65+ years old or having a diagnosis associated with altered bone turnover 
(hyperthyroidism, connective tissue disorder, metastatic bone disease, steroid use and 
osteoporosis under treatment). The latter analysis was performed to control for the 
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TZD-associated decrease in osteoblastogenesis (10) and the SU-associated increase in 
hypoglycaemic events (and possibly the resulting increased risk of falls) (11). 
Statistical analysis Hazard rates of fractures were calculated and compared between 
cohorts, offset by the person-years of exposure using Cox regression in Stata MP 
14.0. Missing data were handled by multiple imputation techniques (chained 
equations with predicted mean matching) and reported in the Supplementary Material. 
This project was authorized by the relevant Scientific Review Committee (SRC 
Reference Number: 16THIN093). 
Results 
Cohort characteristics A total of 22,618 subjects (4,548 patients with T2DM exposed 
to dapagliflozin, thereafter “exposed cohort” and 18,070 patients with T2DM, 
unexposed to SGLT2i, thereafter “control cohort”) constituted the study population. 
The study population was followed-up for a mean of approximately 12.0 months 
(range 36 months) and a total of approximately 23,000 person-years. Men constituted 
43% of the study population and virtually all subjects (99.7%) were over 50 years old. 
The mean age and BMI were 59.4 years and 34.5 kg/m2 respectively, whereas the 
mean duration of diabetes was approximately ten years and the mean HbA1c in the 
total study population was 7.8% (62 mmol/mol).  
A total of 289 fractures were recorded during the observation period, 132 of 
them were fractures of the proximal femoral, vertebrae, distal radius and humerus, 
collectively considered as fragility fractures. The event rate for any fracture was 
estimated at approximately 12 per 1000 person-years in the exposed cohort.  A table 
summarizing key study characteristics on the basis of exposure to dapagliflozin is 
presented in Table 1.  
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Risk of incident fragility fracture No difference in the risk of fragility fracture was 
detected between patients with diabetes who were administered dapagliflozin and 
matched controls (Crude HR: 0.90, 95% CI: 0.59-1.39, p-value = 0.645, Table 2). 
This finding did not change after adjusting for key covariates (Adjusted HR: 0.87, 
95% CI: 0.56-1.35, p-value = 0.531, Table 2).  
Risk of any fracture Similarly, no difference in the risk of any fracture was detected 
between patients with diabetes who were administered dapagliflozin and matched 
controls (Crude HR: 0.93, 95% CI: 0.69-1.23, p-value = 0.601 and aHR: 0.89, 95% 
CI: 0.66-1.20, p-value =0.427, Table 2). 
Sensitivity analyses No differences in the risk of fragility fracture or any fracture were 
detected when limiting the analysis to those patients at a higher risk of fracture and 
their respective controls (aHR: 0.79, 95% CI: 0.41-1.52, p-value = 0.476 and aHR: 
0.99, 95% CI: 0.64-1.55, p-value = 0.981 respectively, Supplementary Table 2). 
Adding use of TZD and SU as covariates in the primary analysis did not change the 
findings (aHR for fragility fracture: 0.87, 95% CI:  0.56-1.36, p-value = 0.476 and 
aHR for any fracture:0.88, 95% CI:   0.66-1.19, p-value = 0.422, Supplementary 
Table 2).  
Discussion 
In this population-based study involving a total of 22,618 individuals with 
T2DM, we report that the risk of fracture is not affected in patients treated with 
dapagliflozin compared to appropriately matched controls receiving standard, 
background antidiabetic medication. This neutral effect of dapagliflozin on the risk of 
fracture (at least in the short-term) in patients with no record of fracture at baseline 
appears to be robust in sensitivity analysis limiting to those considered to be at an 
increased risk for fracture or when modelling the use of sulfonylureas and 
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thiazolidinediones. Our findings are reassuringly based on a total of 289 fractures 
observed during approximately 23000 person-years of follow-up in one of the largest 
to date cohorts of patients treated with dapagliflozin (n=4,548), collectively providing 
relative confidence in our estimates.  
Our findings are also of clinical relevance, considering the prior knowledge of 
the increased risk of fracture in patients with T2DM and evidence suggesting that 
SGLT2i-related skeletal effects may be detrimental (12). Furthermore, the results of 
the sensitivity analyses suggest that the neutral effect of dapagliflozin on fracture risk 
may also apply to those patients with a higher baseline risk of fracture than the 
general diabetic population or even to patients who are usually excluded from trials, 
such as those with metastatic bone disease or those under glucocorticoid treatment. 
Unfortunately, it was not possible to explore the effects of the other SGLT2i, since 
the number of subjects receiving empagliflozin or canagliflozin was too small to 
permit analysis of rare events like the incidence of fractures. 
The underlying pathophysiology between SGLT2i and bone metabolism is 
still unclear. It has been postulated that SGLT2i may lead to elevated serum 
phosphate, resulting in turn in a compensatory increase in PTH levels, thus further 
enhancing bone resorption (12) and that they may induce osmotic diuresis and volume 
depletion, which in turn may increase the susceptibility to falls (13). These effects, 
imposing an additional burden on skeletal health in T2DM, are not specific to a 
compound, instead they are noted with all members of the SLGT2i class. Our findings 
might challenge these postulated mechanisms suggesting a drug class-effect regarding 
fracture risk.  
However, our findings should be considered in light of the study limitations. 
First, the duration of follow-up (mean follow-up a year, maximum follow-up three 
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years and shorter than the CANVAS trial) may not be long enough for a fracture to 
manifest. Therefore, the possibility of a cumulative negative effect on the skeletal 
health, provoked by the progressive accumulation of minimal yet detrimental skeletal 
effects induced by dapagliflozin, which would finally result in a fracture after a 
prolonged drug exposure cannot be excluded. On the other hand, the increase in the 
risk of fracture with SGLT2i was observed within first few weeks after drug initiation 
(4). Hence, our study would have captured this increase, considering its large sample 
size and the adequate follow-up. 
In conclusion, we observed that the risk of treatment-emergent fractures in 
patients with T2DM receiving dapagliflozin is similar to that observed in those 
receiving standard antidiabetic medication. This neutral effect was also observed in 
patients at high risk of fracture. 
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Figure Legends. 
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Table 1: Baseline characteristics of the study population on the basis of exposure to 
dapagliflozin 
 
  Exposed to 
dapagliflozin 
Unexposed cohort 
 
N 4,548 (20.1) 18,070 (79.9) 
Age (years) 59.4 (9.4) 59.4 (9.4) 
Male  1,968 (43.3)  7,829 (43.3) 
Body Mass Index 34.7 (6.8) 34.4 (6.6)  
Current smoking  603 (13.3) 2,903 (16.1)  
Estimated Glomerular Filtration Rate 90.8 (21.8) 87.0 (24.8)  
Townsend   
1 916 (20.1) 3226 (17.9) 
2 841 (18.5) 3377 (18.7) 
3 1047 (23.0) 3874 (21.4) 
4 917 (20.2) 3891 (21.5) 
5 679 (15.0) 3022 (16.7) 
Not available 148 (3.3) 680 (3.8) 
Follow-up (months) 12.9 (8.4) 11.9 (8.2)  
Diabetes-specific characteristics   
Duration (years) 9.9 (5.8) 9.6 (5.7) 
Glycated Hemoglobin A1c (% -
mmol/mol) 
9.1 (3.8)   
75.7 (17.3) 
7.5 (3.8)  
 60.5 (18.8) 
Insulin use 1,226 (26.7)                4,047 
(22.4)  
Drugs or co-morbidities potentially 
affecting risk of fracture 
  
Hyperthyroidism  61 (1.3) 262 (1.5) 
Antiosteoporotic medication 93 (2.0) 466 (2.6) 
Glucocorticoid  289 (6.4) 1,382 (7.7) 
Metastatic bone disease 8 (0.2) 52 (0.3) 
Connective tissue disorder 88 (1.9) 582 (3.2) 
Charlson’s Comorbidity Index   
 13 
1 2115 (46.5) 7874 (43.57) 
2 1446 (31.79) 5456 (30.19) 
3 579 (12.73) 2667 (14.76) 
4 267 (5.87) 1196 (6.62) 
5 or more 141 (3.1) 877 (4.85) 
 
Continuous data presented as mean (standard deviation) unless otherwise specified. 
Dichotomous and ordinal data presented as N (%). Townsend index is a measure of 
material deprivation (1 denotes the least deprived and 5 the most deprived 
individuals) 
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Table 2:  Risk of fragility fracture and any fracture in the exposed cohort compared to standard treatment cohort 
 
 
CI: Confidence Interval, HR: Hazard Rate Ratio, *Adjusted for age, gender, body mass index, smoking, glycated haemoglobin A1c, duration of 
diabetes, insulin use, estimated glomerular filtration rate, social deprivation index, presence of hyperthyroidism, metastatic bone disease or 
connective tissue disorder | P-values derived from Cox regression | Proximal femoral, vertebral, distal radius and humerus fractures were 
considered as fragility fractures.  
 Exposed to 
dapagliflozin 
Controls Crude HR 
(95%CI) 
P-value Adjusted HR* 
(95%CI) 
P-value 
Fragility fracture 
Person-years 4,881.69 17,994.32     
Fragility fracture (events) 26 106     
Event rate (per 1000 
person-years) 
5.33 5.89 0.90 (0.59-1.39) 0.645 0.87 (0.56-1.35) 0.531 
Any fracture 
Person-years 4,851.14 17,892.61     
Any fracture (events) 58 231     
Event rate (per 1000 
person-years) 
11.96 12.91 0.93 (0.69-1.23) 0.601 0.89 (0.66-1.20) 0.427 
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